Tag Archives: Metabolic effects
Previous comparisons between indapamide and HCTZ have been made, for the most part, on the basis of historical controls, ie, results from separate studies have been compared. Such comparisons are at high risk of being confounded. Our direct comparison, though … Continue reading →
POWER CALCULATION Because there was no difference between treatments for the main effect, the post hoc power of the study was calculated to show an effect significant at the 0.05 level if a true difference existed, using standard methods . … Continue reading →
Compliance with study medication was good in both treatment groups. At visit 3, compliance with placebo was 95.42±4.23% in the indapamide group and 99.33±4.51% in the HCTZ group; compliance was above 95% in both groups at all visits, and at … Continue reading →
There were no significant abnormalities (ie, results outside the reference range) in hematology or liver enzyme tests at baseline or end of the study on either treatment.
Results are presented as mean ± SD for the 39 patients who had cholesterol and HDL tests completed at visit 3 (after placebo washout) and visit 9 (after six months on randomized treatment). Among those randomly assigned to HCTZ, 21 … Continue reading →
Routine laboratory tests were carried out in the hospital laboratory. The laboratory tests performed at the beginning (visit 1) and end of the study (visit 9) included the following determinations: platelet and blood cells counts, serum electrolytes (sodium, potassium and … Continue reading →
Fasting blood samples (12 to 14 h) were collected from an arm vein while subjects were reclining in a blood sampling chair, into tubes containing EDTA-Na2 at a final concentration of 0.15%. Plasma was obtained by centrifugation at 1000 g … Continue reading →
Study visits were every two weeks for the first month, then once a month for the remaining six months of the study.
Because the study was an explanatory trial, it was determined a priori to exclude from the main analysis patients with compliance less than 90% of prescribed medication (questioning, counting of tablets), patients with clinical or laboratory adverse effects requiring discontinuation … Continue reading →
Patients eligible for recruitment were men or women aged 18 to 75 years with mild to moderate primary hypertension (sitting systolic pressure 160 mmHg or diastolic pressure 95 to 105 mmHg); untreated or formerly treated with a single first-line antihypertensive … Continue reading →